论文部分内容阅读
目的:观察脑心通对急性冠脉综合征(ACS)血管内皮功能等相关因子的影响程度及安全性。方法:将ACS120例随机分为观察组和对照组各60例,对照组在常规治疗原发病的同时,给予辛伐他汀10mg,每晚1次,阿司匹林肠溶片100mg,每天1次;观察组在对照组用药基础上加用脑心通胶囊,每次4粒,每天3次。两组均治疗3个月,观察两组用药前后氧化亚氮(NO)、血管内皮素-1(ET-1)、纤维蛋白原(FIB)、组织型纤溶酶原激活物抑制物(PAI-1)和组织型纤溶酶原激活物(t-PA)的变化。结果:观察组治疗后NO水平升高,ET-1水平和FIB减低,t-PA活性增强,PAI-1活性降低。与对照组比较,差异显著或非常显著(P<0.05,P<0.01)。两组均未发现不良反应。结论:脑心通能够有效改善ACS患者的血管内皮功能,且安全。
Objective: To observe the effect of Naoxintong on the related factors such as vascular endothelial function in patients with acute coronary syndrome (ACS). Methods: ACS120 cases were randomly divided into observation group (60 cases) and control group (60 cases). Simvastatin 10 mg and aspirin 100 mg once daily were given to the control group in the routine treatment of primary disease. Group in the control group based on the addition of Naoxintong capsules, each 4, 3 times a day. Both groups were treated for 3 months. The changes of nitric oxide (NO), endothelin-1 (ET-1), fibrinogen (FIB), tissue plasminogen activator inhibitor -1) and tissue-type plasminogen activator (t-PA) changes. Results: In the observation group, NO level increased, ET-1 level and FIB decreased, t-PA activity increased and PAI-1 activity decreased. Compared with the control group, the difference was significant or very significant (P <0.05, P <0.01). No adverse reactions were found in both groups. Conclusion: Naoxintong can effectively improve the endothelial function of ACS patients and is safe.